Canadian Study: Closed-Loop Insulin Pumps Reduce Dangerous Lows for New Moms with Type 1 Diabetes

A study from Canada is offering new hope for one of the most challenging — and often overlooked — periods in a woman's diabetes journey: the weeks after giving birth. Researchers at the University of Calgary's Cumming School of Medicine found that closed-loop insulin delivery systems dramatically reduced dangerous low blood sugar episodes in new mothers with Type 1 diabetes during the first six months postpartum.

What the Researchers Did

This randomized controlled trial followed 18 women with Type 1 diabetes through the first 24 weeks after delivery. Half were assigned to a hybrid closed-loop system — specifically the MiniMed 670G/770G in "automode," which automatically adjusts insulin delivery based on continuous glucose readings. The other half used sensor-augmented pump therapy, which monitors blood sugar but requires the patient to manually manage insulin doses. After 12 weeks, all participants switched to the closed-loop system through week 24.

Key Findings — In Plain English

Both groups spent a similar amount of time with blood sugar in the healthy target range of 70–180 mg/dL (about 79% for the closed-loop group vs. 78% for the manual group) — a reassuring baseline. But where the difference became striking was in low blood sugar events:

• The closed-loop group spent only 1.7% of time below 70 mg/dL compared to 5.5% in the manual group — more than three times less.
• For severely low readings below 54 mg/dL (a dangerous threshold), the closed-loop group spent just 0.3% of time there vs. 1.1% — nearly four times less.
• Importantly, there were zero episodes of diabetic ketoacidosis or severe hypoglycemia in either group throughout the study.

Why This International Perspective Matters

Canada's universal healthcare system allowed researchers to study a real-world postpartum population without the insurance and access barriers common in the US. While the sample size is small, the findings align with and extend the growing body of evidence supporting closed-loop technology — but specifically address the postpartum window, which has historically been understudied in American clinical trials.

Comparing to US Guidelines

Current American Diabetes Association (ADA) Standards of Care recommend that people with Type 1 diabetes spend more than 70% of time in the 70–180 mg/dL range and less than 4% of time below 70 mg/dL. The closed-loop group in this study comfortably met both benchmarks. The manual group, at 5.5% below 70 mg/dL, exceeded the ADA's acceptable threshold — a meaningful safety concern for breastfeeding mothers and newborn caregivers.

Why This Matters for US Patients

For American women with Type 1 diabetes, the postpartum period is a "perfect storm" of hormonal shifts, sleep deprivation, and unpredictable schedules — all of which disrupt blood sugar control. Hypoglycemia is not just dangerous for the mother; it can impair the alertness needed to care for a newborn. This Canadian research provides strong reassurance that closed-loop systems like the MiniMed 670G/770G — already FDA-approved and available in the US — are safe and effective postpartum. US patients should discuss this option with their endocrinologist and verify coverage with their insurer, as access remains a key barrier stateside.

Citation

Donovan LE, Feig DS, Lemieux P, et al. A Randomized Trial of Closed-Loop Insulin Delivery Postpartum in Type 1 Diabetes. Diabetes Care. 2023. DOI: 10.2337/dc23-0882. PMID: 37824779.